IP Library Granted Patent US 7,211,589
Granted Patent B2
US 7,211,589 · App. 10/471,025 · Granted May 1, 2007

Atisane compounds and use thereof

Assignee: Eisai R&D Management Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,211,589
App. No.
10/471,025
Granted
May 1, 2007
Kind
B2
Abstract

The present invention provides a novel compound exhibiting an excellent suppressing effect to cell injury caused by radicals and neurotoxicity induced by excitatory nuerotransmitters such as glutamate. Specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein Z represents a bivalent organic group and the like of from 2 to 3 carbon atom(s) which may have a substituent; and R 3 represents a carboxyl group and the like.

Claims (96)

1. A compound represented by the following formula, or a salt thereof or a hydrate thereof:

wherein Z is a group represented by the formula:

wherein Q 1 is

wherein A 1 represents an optionally substituted C 1-6 alkylene group or a single bond;

X 1 represents a halogen atom or a cyano group;

X 2 represents the formula —S(O) m —, an oxygen atom, a carbonyl group or a single bond, wherein m of —S(O) m — is an integer of 0, 1 or 2;

R 4a represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 6-14 aromatic hydrocarbon cyclic group, an optionally substituted from 5- to 14-membered aromatic heterocyclic group, an optionally substituted C 1-6 alkoxy group or a hydroxyl group; and

R 4b and R 4c are independent of each other and each represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 6-14 aromatic hydrocarbon cyclic group, an optionally substituted from 5- to 14-membered aromatic heterocyclic group, an optionally substituted C 2-7 acyl group or an optionally substituted C 1-6 alkylsulfonyl group;

Q 2a represents a hydrogen atom, a halogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 1-6 alkoxy group, a hydroxyl group or a group represented by the formula —NR 6a R 6b , wherein R 6a and R 6b are independent of each other and each represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 2-7 acyl group or an optionally substituted C 1-6 alkylsulfonyl group:

R 3a represents a carbonyl group, a methylene group or a single bond; and

R 3b represents a hydrogen atom, a halogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 1-6 alkoxy group, a hydroxyl group, a cyano group or a group represented by the formula —NR 5a R 5b ,

wherein R 5a and R 5b are independent of each other and each represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 6-14 aromatic hydrocarbon cyclic group, an optionally substituted from 5- to 14-membered aromatic heterocyclic group, an optionally substituted C 2-7 acyl group or an optionally substituted C 1-6 alkylsulfonyl group, provided that the following cases (1) to (3) are excluded:

(1) Z represents a 1,2-dicarboxyethane-1,2-yl group or a 1,2-dimethoxycarbonylethane-1,2-yl group, and the formula —R 3a –R 3b represents a hydroxymethyl group or an acetoxymethyl group;

(2) Z represents a 1-i-propylethane-1,2-yl group and the formula —R 3a –R 3b represents a hydrogen atom; and

(3) the formula —R 3a –R 3b represents a methyl group, and Z represents the formula:

wherein R 11 represents a hydrogen atom or a methyl group, and R 12 represents a hydroxyl group, a methyl group or a tetrahydropyran-2H-pyran-2-yl-oxy group.

2. The compound, according to claim 1 , a salt thereof or a hydrate thereof, wherein said compound of formula (I) is a compound of formula (Ia):

wherein Z, R 3a and R 3b respectively represent those defined for the above Z, R 3a and R 3b in claim 1 , provided that the following cases (1) to (3) are excluded:

(1) Z represents a 1,2-dicarboxyethane-1,2-yl group or a 1,2-dimethoxycarbonylethane-1,2-yl group, and the formula —R 3a –R 3b represents a hydroxymethyl group or an acetoxymethyl group;

(2) Z represents a 1-i-propylethane-1,2-yl group and the formula —R 3a –R 3b represents a hydrogen atom; and

(3) the formula —R 3a –R 3b represents a methyl group, and Z represents the formula:

wherein R 11 represents a hydrogen atom or a methyl group, and R 12 represents a hydroxyl group, a methyl group or a tetrahydropyran-2H-pyran-2-yl-oxy group.

3. The compound according to claim 1 , a salt thereof or a hydrate thereof,

wherein Q 1 is

wherein A 1 , X 2 and R 4a respectively represent those defined for A 1 , X 1 and R 4a in claim 1 .

4. The compound according to claim 1 , a salt thereof or a hydrate thereof, wherein Z is a group represented by the formula:

wherein Q 1 and Q 2a respectively represent those defined for Q 1 and Q 2a in claim 1 .

5. The compound according to claim 1 , a salt thereof or a hydrate thereof,

wherein Q 1 is

wherein A 1 , X 2 , R 4b and R 4c respectively represent those defined for A 1 , X 2 , R 4b and R 4c in claim 1 .

6. The compound according to claim 1 , a salt thereof or a hydrate thereof, wherein R 3a is a carbonyl group.

7. A compound represented by the following formula, or a salt thereof or a hydrate thereof:

wherein Z represents a bivalent organic group of from 2 to 3 carbon atoms, provided that Z may have one or two group(s) selected from the group consisting of those represented by the following formula:

wherein A 1 represents an optionally substituted C 1-6 alkylene group or a single bond;

X 1 represents a halogen atom or a cyano group;

X 2 represents the formula —S(O) m —, an oxygen atom a carbonyl group or a single bond, wherein m of —S(O) m — is an integer of 0, 1 or 2;

R 4a represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 6-14 aromatic hydrocarbon cyclic group, an optionally substituted from 5- to 14-membered aromatic heterocyclic group, an optionally substituted C 1-6 alkoxy group or a hydroxyl group; and

R 4b and R 4c are independent of each other and each represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 6-14 aromatic hydrocarbon cyclic group, an optionally substituted from 5- to 14-membered aromatic heterocyclic group, an optionally substituted C 2-7 acyl group or an optionally substituted C 1-6 alkylsulfonyl group;

wherein in the case where Z is a 1,2-ethylene group not having a substituent or a 1,2-vinylene group not having a substituent is excluded;

R 3a represents a carbonyl group, a methylene group or a single bond; and

wherein R 3b is a hydroxyl group.

8. The compound according to claim 1 , a salt thereof or a hydrate thereof, wherein Q 2a is a hydroxyl group.

9. A compound represented by the following formula, or a salt thereof or a hydrate thereof:

wherein Z is a group represented by the formula:

wherein Q 1 is a group represented by the formula -A 1 -S(O) m —R 4a , wherein A 1 represents an optionally substituted C 1-6 alkylene group or a single bond, m is an integer of 0, 1 or 2, and R 4a represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 6-14 aromatic hydrocarbon cyclic group, an optionally substituted from 5- to 14-membered aromatic heterocyclic group, an optionally substituted C 1-6 alkoxy group or a hydroxyl group;

wherein Q 2 represents a group represented by the formula:

wherein A 1 represents an optionally substituted C 1-6 alkylene group or a single bond;

X 1 represents a halogen atom or a cyano group;

X 2 represents the formula —S(O) m —, an oxygen atom, a carbonyl group or a single bond, wherein m of —S(O) m — is an integer of 0, 1 or 2;

R 4a represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 6-14 aromatic hydrocarbon cyclic group, an optionally substituted from 5- to 14-membered aromatic heterocyclic group, an optionally substituted C 1-6 alkoxy group or a hydroxyl group; and

R 4b and R 4c are independent of each other and each represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 6-14 aromatic hydrocarbon cyclic group, an optionally substituted from 5- to 14-membered aromatic heterocyclic group, an optionally substituted C 2-7 acyl group or an optionally substituted C 1-6 alkylsulfonyl group;

wherein in the case where Z is a 1,2-ethylene group not having a substituent or a 1,2-vinylene group not having a substituent is excluded;

R 3a represents a carbonyl group, a methylene group or a single bond; and

R 3b represents a hydrogen atom, a halogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 1-6 alkoxy group, a hydroxyl group, a cyano group or a group represented by the formula —NR 5a R 5b ,

wherein R 5a and R 5b are independent of each other and each represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 6-14 aromatic hydrocarbon cyclic group, an optionally substituted from 5- to 14-membered aromatic heterocyclic group, an optionally substituted C 2-7 acyl group or an optionally substituted C 1-6 alkylsulfonyl group,

provided that the following cases (1) to (3) are excluded:

(1) Z represents a 1,2-dicarboxyethane-1,2-yl group or a 1,2-dimethoxycarbonylethane-1,2-yl group, and the formula —R 3a –R 3b represents a hydroxymethyl group or an acetoxymethyl group;

(2) Z represents a 1-i-propylethane-1,2-yl group and the formula —R 3a –R 3b represents a hydrogen atom; and

(3) the formula —R 3a –R 3b represents a methyl group, and Z represents the formula:

wherein R 11 represents a hydrogen atom or a methyl group, and R 12 represents a hydroxyl group, a methyl group or a tetrahydropyran-2H-pyran-2-yl-oxy group.

10. The compound according to claim 1 , a salt thereof or a hydrate thereof, wherein R 4a is an optionally substituted methyl group, an optionally substituted ethyl group, an optionally substituted n-propyl group or an optionally substituted i-propyl group.

11. The compound according to claim 1 , a salt thereof or a hydrate thereof, wherein A 1 is a methylene group.

12. A compound represented by the following formula, or a salt thereof or a hydrate thereof:

wherein Z represents a bivalent organic group of from 2 to 3 carbon atoms, provided that Z may have one or two group(s) selected from the group consisting of those represented by the following formula:

wherein A 1 represents an optionally substituted C 1-6 alkylene group or a single bond;

X 1 represents a halogen atom or a cyano group;

X 2 represents the formula —S(O) m —, wherein m is 1;

R 4a represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 1-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 6-14 aromatic hydrocarbon cyclic group, an optionally substituted from 5- to 14-membered aromatic heterocyclic group, an optionally substituted C 1-6 alkoxy group or a hydroxyl group; and

R 4b and R 4c are independent of each other and each represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 6-14 aromatic hydrocarbon cyclic group, an optionally substituted from 5- to 14-membered aromatic heterocyclic group, an optionally substituted C 2-7 acyl group or an optionally substituted C 1-6 alkylsulfonyl group;

wherein in the case where Z is a 1,2-ethylene group not having a substituent or a 1,2-vinylene group not having a substituent is excluded;

R 3a represents a carbonyl group, a methylene group or a single bond; and

R 3b represents a hydrogen atom, a halogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 1-6 alkoxy group, a hydroxyl group, a cyano group or a group represented by the formula —NR 5a R 5b ,

wherein R 5a and R 5b are independent of each other and each represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 2-6 alkenyl group, an optionally substituted C 2-6 alkynyl group, an optionally substituted C 6-14 aromatic hydrocarbon cyclic group, an optionally substituted from 5- to 14-membered aromatic heterocyclic group, an optionally substituted C 2-7 acyl group or an optionally substituted C 1-6 alkylsulfonyl group,

provided that the following cases (1) to (3) are excluded:

(1) Z represents a 1,2-dicarboxyethane-1,2-yl group or a 1,2-dimethoxycarbonylethane-1,2-yl group, and the formula —R 3a –R 3b represents a hydroxymethyl group or an acetoxymethyl group;

(2) Z represents a 1-i-propylethane-1,2-yl group and the formula —R 3a –R 3b represents a hydrogen atom; and

(3) the formula —R 3a –R 3b represents a methyl group, and Z represents the formula:

wherein R 11 represents a hydrogen atom or a methyl group, and R 12 represents a hydroxyl group, a methyl group or a tetrahydropyran-2H-pyran-2-yl-oxy group.

13. The compound according to claim 1 , a salt thereof or a hydrate thereof, wherein A 1 represents a C 1-6 alkylene group or a single bond; R 4a represents a hydrogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 6-14 aromatic hydrocarbon cyclic group, a 5- to 14-membered aromatic heterocyclic group, a C 1-6 alkoxy group or a hydroxyl group; R 4b and R 4c are independent of each other and each represents a hydrogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 6-14 aromatic hydrocarbon cyclic group, a 5- to 14-membered aromatic heterocyclic group, a C 2-7 acyl group or a C 1-6 alkylsulfonyl group; and R 3b represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 1-6 alkoxy group, a hydroxyl group, a cyano group or a group represented by the formula —NR 5a R 5b wherein R 5a and R 5b are independent of each other and each represents a hydrogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 6-14 aromatic hydrocarbon cyclic group, a 5- to 14-membered aromatic heterocyclic group, a C 2-7 acyl group or a C 1-6 alkylsulfonyl group.

14. The compound according to claim 1 , a salt thereof or a hydrate thereof, wherein Q 2a represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 1-6 alkoxy group, a hydroxyl group or a group represented by the formula —NR 6a R 6b , wherein R 6a and R 6b are independent of each other and each represents a hydrogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 2-7 acyl group or a C 1-6 alkylsulfonyl group.

15. A pharmaceutical composition comprising the compound according to claim 1 , a salt thereof or a hydrate thereof; and

a pharmaceutically acceptable carrier.

16. A pharmaceutical composition comprising the compound according to claim 7 , a salt thereof or a hydrate thereof; and

a pharmaceutically acceptable carrier.

17. A pharmaceutical composition comprising the compound according to claim 9 , a salt thereof or a hydrate thereof; and

a pharmaceutically acceptable carrier.

18. A pharmaceutical composition comprising the compound according to claim 12 , a salt thereof or a hydrate thereof; and

a pharmaceutically acceptable carrier.

19. A method for treating a disease or condition selected from the group consisting of glaucoma, retinopathy of prematurity, diabetic retinopathy, macular degeneration, hearing disorder, atopic dermatitis, contact dermatitis or hyperesthesia, said method comprising:

administering a pharmacologically effective amount of the compound according to claim 1 , a salt thereof or a hydrate thereof to a patient with said disease or condition.

20. A method for treating a disease or condition selected from the group consisting of glaucoma, retinopathy of prematurity, diabetic retinopathy, macular degeneration, hearing disorder, atopic dermatitis, contact dermatitis or hyperesthesia, said method comprising:

administering a pharmacologically effective amount of the compound according to claim 7 , a salt thereof or a hydrate thereof to a patient with said disease or condition.

21. A method for treating a disease or condition selected from the group consisting of glaucoma, retinopathy of prematurity, diabetic retinopathy, macular degeneration, hearing disorder, atopic dermatitis, contact dermatitis or hyperesthesia, said method comprising:

administering a pharmacologically effective amount of the compound according to claim 9 , a salt thereof or a hydrate of them to a patient with said disease or condition.

22. A method for treating a disease or condition selected from the group consisting of glaucoma, retinopathy of prematurity, diabetic retinopathy, macular degeneration, hearing disorder, atopic dermatitis, contact dermatitis or hyperesthesia, said method comprising:

administering a pharmacologically effective amount of the compound according to claim 12 , a salt thereof or a hydrate thereof to a patient with said disease or condition.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2007
From: EISAI CO., LTD.
To: EISAI R&D MANAGEMENT CO., LTD.
Reel/Frame 019500/0673 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT SERIAL NUMBER FROM 10/147025 TO 10/471,025. DOCUMENT PREVIOUSLY RECORDED AT REEL 014576 FRAME 0455. Recorded Oct 1, 2004
From: AKAIKE, AKINORI; SUGIMOTO, HACHIRO; NISHIZAWA, YUKIO; YONAGA, MASAHIRO; ASAKAWA, NAOKI; ASAI, NAOKI; MANO, NARIYASU; TERAUCHI, TARO; DOKO, TAKASHI
To: EISAI CO., LTD.
Reel/Frame 015207/0107 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2003
From: AKAIKE, AKINORI; SUGIMOTO, HACHIRO; NISHIZAWA, YUKIO; YONAGA, MASAHIRO; ASAKAWA, NAOKI; ASAI, NAOKI; MANO, NARIYASU; TERAUCHI, TARO; DOKO, TAKASHI
To: EISAI CO., LTD.
Reel/Frame 014576/0455 →
Priority Claims (1)
JP 2001-133209 · Apr 27, 2001 · national
Continuity (1)
Related Publication 20040180930A1 · Sep 16, 2004